Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab vs SoC in untreated advanced nccRCC
NCT03075423Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Nov 2017
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Goethe University Frankfurt. Started Nov 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT03075423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075423.